Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Calibration Tools Used to Enhance Ultralow Field MRI Technology

By BiotechDaily International staff writers
Posted on 16 Dec 2013
Image: NIST physicist Michael Boss positions a prototype NIST phantom in an ultralow-field magnetic resonance imaging scanner at the University of California at Berkeley. NIST phantoms are intended to help assess and validate this experimental imaging method, which offers advantages in diagnosing and monitoring of certain medical conditions (Photo courtesy of NIST).
Image: NIST physicist Michael Boss positions a prototype NIST phantom in an ultralow-field magnetic resonance imaging scanner at the University of California at Berkeley. NIST phantoms are intended to help assess and validate this experimental imaging method, which offers advantages in diagnosing and monitoring of certain medical conditions (Photo courtesy of NIST).
A US technology office has developed prototype calibration tools for an experimental medical imaging technique that offers new benefits in diagnosing and tracking of specific cancers and other medical disorders.

The US National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) designed, built, and evaluated two prototype phantoms for calibrating ultralow-field (ULF) magnetic resonance imaging (MRI) systems.

The NIST prototypes are the first standard calibration tools for ULF-MRI, offering a quantitative means to assess performance, validate the technique, and directly compare different experimental and clinical MRI scanners. “Tissues that may look the same in clinical MRI can look very different in ULF-MRI, which provides new contrast mechanisms,” NIST physicist Dr. Michael Boss stated. “Our hope is that we can move this technique along to attract more interest from [industry] vendors.”

MRI noninvasively images soft tissues based on measurements of how hydrogen nuclei respond to magnetic fields. ULF-MRI enhances tissue contrast in specific types of MRI scans. Prostate tumors, for example, can be difficult to see with conventional MRI but show up clearly under ULF-MRI. ULF-MRI has also been used in research approaches to image the brain, and assessed in at least one nonmedical application, inspection of liquids at airports.

ULF-MRI also offers practical advantages: the systems are more streamlined, lighter in weight, and less costly than conventional MRI scanners. That is because ULF-MRI operates at much lower magnetic field strengths, measured in micro-Teslas, thousands of times lower than conventional MRI, which operates at up to 3 Teslas and requires large magnets. The low magnetic field strength means ULF-MRI requires the most sensitive magnetometers available: superconducting quantum interference devices (SQUIDs). This is convenient in that it makes ULF-MRI suitable for combining with other SQUID-based imaging techniques such as magnetoencephalography.

NIST scientists earlier designed phantoms for standard MRI systems and also have extensive experience both making and using SQUIDs. NIST’s new ULF-MRI phantoms are short plastic cylinders, shaped like hockey pucks but a bit smaller, containing six or 10 plastic jars filled with various salt solutions that become magnetized in a magnetic field. Each phantom measures a different aspect of scanner performance such as spatial resolution. NIST researchers tested the new phantoms on both a conventional MRI system at the University of Colorado Health Sciences Center (Denver, CO, USA) and a research ULF-MRI scanner at the University of California (UC) at Berkeley, where the technique was first demonstrated about than 10 years ago.

Tests findings revealed that the prototype phantoms are well matched to ULF-MRI applications and they allow direct comparison of ULF and clinical MRI system performance. NIST researchers now plan to integrate design improvements based on lessons gleaned from the prototypes, with the aim of improving phantom stability and providing traceability to standard measurement units. NIST and the University of California (UC) Berkeley (USA) researchers also plan to work together to develop ULF-MRI technology for the detection of prostate and breast cancers.

NIST’s phantoms for conventional MRI systems are currently being tested by hospitals and MRI manufacturers, and Sigma-K Corp. (Durham, NC, USA) is devising ways for making copies for more widespread distribution under a NIST Small Business Innovation Research Award (SBIR).

The study’s findings were published online November 26, 2013, in the journal Magnetic Resonance in Medicine.

Related Links:

National Institute of Standards and Technology
University of California, Berkeley
Sigma-K



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.